BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ceretec, Inc., Medical Device and Pharmaceutical Product Innovators, Introduces NO-Diff(TM), a Nitric Oxide Lung Diffusion Gas Mixture


10/16/2012 11:12:56 AM

LAS VEGAS, Oct. 16, 2012 /PRNewswire/ -- Ceretec, Inc. today announced that it has introduced an FDA-listed nitric oxide gas product (NO-Diff Nitric Oxide 800 ppm Lung Diffusion Mixture) for use in membrane diffusing capacity (DLNO) testing in pulmonary function laboratories in the U.S.

Ceretec's NO-Diff is a gas product classified by the FDA as a Class 1 medical device; however, it will be produced for Ceretec by its medical gas partner in a pharmaceutical GMP facility. Alex Stenzler, Ceretec's Vice President, explained, "Use of nitric oxide gas for diffusing capacity testing offers new insights into the structure of the alveolar-capillary membrane, which is important for understanding the progression of diseases that affect the lungs such as interstitial pulmonary fibrosis." He added, "We will be offering this gas only to institutions who have approval to perform this diagnostic pulmonary function measurement so as to not induce infringement of patents held by Ikaria Corporation that expire in January 2013." Ceretec anticipates a generic pharmaceutical nitric oxide product will enter the U.S. market after regulatory approval for distribution and following the expiration of the relevant Ikaria patents.

Nitric oxide gas is one of the most important molecules naturally produced in the human body. It performs functions in every organ system and is responsible for vessel tone, the body's natural defense mechanisms as well as cell growth and healing functions.

About Ceretec, Inc.

Ceretec is a privately held corporation that is managed by a group of industry veterans involved in developing and producing innovative, cutting-edge medical device and pharmaceutical products.

Contact Information:

Alex Stenzler
Vice President, Technology Acquisition
Ceretec, Inc.
Phone 714-823-3468
Email: alex.stenzler@ceretecinc.com
www.ceretecinc.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Ceretec, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES